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Abstract
Background: Candidemia is an increasing problem in tertiary care hospitals worldwide. Here, we report the first
outbreak of candidemia caused by fluconazole-resistant C. parapsilosis (FRCP) strains in Brazil.
Methods: This was a cross-sectional study of clinical and microbiological data of all candidemic episodes diagnosed
from July 2011 to February 2012 in a 200-bed tertiary care hospital. Initial yeast identification and susceptibility testing
were performed using the VITEK 2 - System. Isolates of Candida spp. resistant to fluconazole were sent to a reference
laboratory (LEMI-UNIFESP) for further molecular identification and confirmation of resistance by CLSI microdilution test.
A multivariate analysis was conducted to identify factors associated with FRCP infection.
Results: We identified a total of 40 critically ill patients with candidemia (15 women) with a median age of 70 years.
The incidence of candidemia was 6 cases/1,000 patients admissions, including 28 cases (70 %) of infection with C.
parapsilosis, 21 of which (75 %) were resistant to fluconazole. In only 19 % of FRCP candidemia cases had fluconazole
been used previously. The results of our study indicated that diabetes is a risk factor for FRCP candidemia (p = 0.002).
Overall, mortality from candidemia was 45 %, and mortality from episodes of FRCP infections was 42.9 %.
Conclusions: The clustering of incident cases in the ICU and molecular typing of strains suggest horizontal
transmission of FRCP. Accurate vigilant monitoring for new nosocomial strains of FRCP is required.
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Background
Hematogenous candidiasis is an alarming problem in
tertiary care hospitals worldwide, especially in patients
admitted in intensive care units (ICU) [1, 2]. Incidence
rates of candidemia vary considerably among geographic
areas and medical centers. For example, in Europe and
the USA, different studies have reported incidence rates
of 0.2–1.87 and 0–2.4 per 1,000 admissions, respectively
[3, 4]. In Brazil and Latin America, nosocomial candide-
mia is an important problem in adults and children, and
the reported incidence rates are 0.33–6 cases per 1,000
hospital admissions [5–7]. The large variation in the in-
cidence rates of candidemia is probably due to a
combination of several factors, including differences in
resources available for medical care and training pro-
grams, difficulties in the implementation of infection
control programs in hospitals in developing countries,
limited number of health care workers to assist patients
in critical care units, and less-aggressive practices of em-
pirical antifungal therapy and prophylaxis for high-risk
patients [6]. Hospital-acquired candidemia is associated
with a large increase in hospitalization duration, attribut-
able mortality (up to 40 %) and costs [8, 9].
Although Candida albicans is still considered the
main causative species of candidemia worldwide, there is
a concern over the rise in invasive infections caused by
non-albicans species. In this regard, Candida glabrata
has frequently been reported in Northern Europe and
US medical centers [1, 10], whereas Candida parapsilo-
sis and Candida tropicalis are the most common non-
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albicans species associated with fungemia in Latin
America and Asia [11, 12]. Of note, a recent multicenter
study in the USA found that C. parapsilosis was the sec-
ond most commonly encountered non-Candida albicans
species [13].
Fluconazole is accepted as an alternative treatment for
patients with candidemia due to its efficacy and safety
demonstrated by several clinical trials [14, 15]. For can-
didemia caused by Candida parapsilosis complex, in
particular, fluconazole has been suggested as the best
alternative for primary therapy [16]. There are some
controversies in the literature regarding the effectiveness
of echinocandins against infections of C parapsilosis, as
high MICs are usually observed when this species is
tested against drugs of this class [17].
During July-2011 and February-2012, we observed a
dramatic increase in the incidence of candidemia re-
ported in ICU patients from a single institution com-
pared to the previous period between January-2006 and
June-2011, where 70 % of all episodes enrolled C. para-
psilosis strains (Fig. 1). We were able to type 09 out 28
C. parapsilosis strains enrolled in this outbreak and they
were considered genetically related [18]. Further antifun-
gal susceptibility tests confirmed that most isolates were
resistant to fluconazole. The present publication de-
scribes clinical and epidemiological data related to
this outbreak of fluconazole resistant C. parapsilosis
candidemia complementing information that was not
explored in our previous report on molecular typing
and resistance mechanisms related to the mentioned
strains [18].
Methods
We conducted a cross sectional study of clinical and
laboratory data of all adult patients (age ≥18 years)
diagnosed with candidemia during their hospitalization
in intensive care unit between July, 2011 and February,
2012 (eight months period) to investigate a candidemia
outbreak. Our local ethical committee approved the
protocol (CEP: 73/2011).
Laboratory procedures
Yeast identification and antifungal susceptibility testing
were initially performed by the local microbiology la-
boratory using the VITEK 2 - system (bioMérieux,
Marcy-I’Étoile, France). All C. parapsilosis isolates stored
at the routine laboratory were sent to a reference labora-
tory (LEMI - Laboratório Especial de Micologia, Univer-
sidade Federal de São Paulo, São Paulo-SP, Brazil) for
further molecular identification and confirmation of an-
tifungal susceptibility testing by the Clinical and Labora-
tory Standards Institute (CLSI) reference method.
(i). Molecular identification of C. parapsilosis (sensu
lato) isolates by real time TaqMan®PCR assays.
DNA was extracted from the isolates using
mechanical disruption with glass beads and phenol/
chloroform [19]. Real-time PCR was performed
using species-specific TaqMan® probes, as previ-
ously described by our group [20].
(ii). In vitro susceptibility testing. Antifungal
susceptibility testing was performed at the reference
laboratory using the CLSI microdilution assay [21].
Fluconazole and anidulafungin were provided by
Pfizer Pharmaceutical Group (New York, NY, USA)
and amphotericin B was provided by Sigma
Chemical Corporation (St. Louis, MO, USA). The
CLSI-M27-S4 document was used as the gold stand-
ard interpretative guidelines for classifying the C.
parapsilosis (sensu lato) isolates as susceptible,
susceptible dose dependent (SDD)/intermediate, or
resistant to azoles and echinocandins [22].
Statistical analysis
We performed univariate and multivariate analyses to
identify risk factors associated with FRCP. For the
Fig. 1 Incidence rates of candidemia and prevalence of Candida parapsilosis in ICU patients admitted at a single institution between 2006
and 2012
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univariate analysis, categorical variables were compared
using the chi-square or Fisher exact tests, and continu-
ous variables were compared using the Student t test or
Mann–Whitney U test, as appropriate. All statistical
tests were two-tailed, and the significance level was set
at p < 0.05.
After the initial univariate analysis, the variables with
significant FRCP association were included in a multi-
variable analysis with adjustments for the covariates of
age and gender. A Poisson regression with robust vari-
ance (linear-log) was employed for the multivariate ana-
lysis. The level of significance was set at p < 0.05 [23].
Results
During the study period, 40 episodes of candidemia were
reported in ICU patients. The median age of the patients
was 70 years (range: 23–91 years), and 37.5 % of the pa-
tients were female. The overall incidence of candidemia
during the eight month study period was 6 cases/1,000
patients-day admissions.
The VITEK 2 system identified 28 blood stream Candida
isolates as C. parapsilosis (70 %), 9 as C. albicans (22.5 %),
2 as C. glabrata (5 %) and 1 as C. tropicalis (2.5 %). Using
the VITEK 2 system, fluconazole resistance or SDD was de-
tected in 21 out 28 C. parapsilosis (75 %) isolates tested. All
9 C. albicans, 2 C. glabrata and 1 C. tropicalis strains were
considered susceptible to fluconazole by the automated
system. All 40 Candida spp strains were susceptible to
amphotericin B and anidulafungin.
Fourteen out 28 clinical strains of C. parapsilosis iso-
lates enrolled into the outbreak had been stored by the
routine laboratory and were available to be sent to the
reference laboratory (LEMI-UNIFESP) for further mo-
lecular identification and confirmation of antifungal sus-
ceptibility test results by the CLSI broth microdilution
(BMD) reference method. Except for one clinical isolate
identified as C. metapsilosis, all other strains were genet-
ically identified as C. parapsilosis (sensu stricto) when
tested using species specific TaqMan® probes. Despite
some differences among MICs generated by the two
methods, the categorical agreement between VITEK 2
and CLSI BMD was very good (72 %). A total of 11 out
14 C parapsilosis strains categorized as SDD or resistant
to fluconazole by the VITEK 2 system, were considered
resistant or SDD when tested by the CLSI method. Of
note, 9 of the 11 strains categorized as resistant to flu-
conazole by the BMD exhibited similar genetic profile
by microsatellite assay and molecular mechanisms re-
lated to azole resistance as reported by our group else-
where [18]. No strains of C. albicans, C. tropicalis or C.
glabrata were available for testing by the CLSI method-
ology. No strains of C. parapsilosis were resistant to ani-
dulafungin or amphotericin B as already documented by
the VITEK 2 system.
Considering that only 14 of the 40 isolated strains
were tested by the CLSI method, we used the informa-
tion provided by the VITEK 2 system to check for risk
factors associated with infection by fluconazole-SDD or
-resistant Candida.
The epidemiological and clinical characteristics of the
patients infected by FRCP strains and those infected by
fluconazole-susceptible Candida (FSC) species are pre-
sented in Table 1. In general, most demographic and
clinical data were similar between the two patient
groups. The exposition to central venous catheter,
hemodialysis, surgery, mechanical ventilation, antibiotics
and corticosteroids, were similar in both groups. It is
important to mention that only 4 of the 21 patients
(19 %) infected by FRCP had been previously exposed to
fluconazole before developing candidemia compared to
3 of the 19 patients (15.8 %) infected by FSC strains
(p = 1). After univariate analysis, only 2 variables
were identified as independent factors associated
with infection by FRCP: diabetes mellitus (p = 0.013)
and parenteral nutrition (p = 0.059). After multivari-
ate analysis, only diabetes remained an independent
factor associated with infection by FRCP (p = 0.001
OR 1.3–3.5).
The overall candidemia mortality rates at 30 days after
diagnosis were 45 % (18/40) for all patients, 47.4 % (9/
19) for the group infected by FSC and 42.9 % (9/21) for
the group infected by FRCP (p = 0.8). Of note, liposomal
amphotericin B was the major therapeutic option
employed for the treatment of patients infected by FRCP
(12 out 21 patients, 57 %).
Discussion
This study is the first to describe an outbreak of candi-
demia caused by fluconazole-resistant C. parapsilosis
strains in ICU patients of a tertiary care hospital in
Brazil. It is important to note that the C. parapsilosis
strains were identified by molecular methods and the
phenotype of resistance to fluconazole was examined by
2 different methods, including the CLSI BMD assay.
The outbreak of C. parapsilosis was confirmed by a
sharp increase in the incidence rate of candidemia re-
ported in the ICU as well as by molecular typing of the
isolates by microsatellite technique (please, see data
about molecular typing on reference Souza et al. 2015).
During the study period, hospital physicians worked
under the reasonable assumption that most episodes of
C. parapsilosis candidemia were completely refractory to
treatment with fluconazole (personal communication).
As a consequence, the hospital staff decided to use lipo-
somal amphotericin B (L-AMB) as the antifungal drug
of choice to treat all episodes of C. parapsilosis candide-
mia. This decision was based on the putative limitations
of echinocandins against C. parapsilosis infections and
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the good activity of L-AMB against biofilm-producing
strains of Candida species [14, 24].
Despite treatment with L-AMB, the crude mortality
rate of candidemia due to fluconazole resistant C. para-
psilosis was 42.9 %. Indeed, this finding contradicts the
current consensus that the mortality rate due to
infection with C. parapsilosis is usually lower than those
due to infection with C. albicans or C. tropicalis [13].
The high mortality rates observed with our casuistic
study of FRCP candidemia is probably secondary to the
high percentage of elderly patients (70 % >60 years) as
well as the high Apache II score related to those patients
(see Table 1).
Although uncommon, invasive infections due to FRCP
isolates have been increasingly reported. In accordance
with recent studies, using antifungal susceptibility tests
that are considered gold standards (CLSI and EUCAST-
European committee on Antimicrobial Susceptibility
Testing, microbroth assays), the rates of fluconazole re-
sistance in blood stream C. parapsilosis isolates ranges
from 3.4 to 7.5 % in the USA [17, 25, 26], 0 to 6.3 % in
Europe and up to 5.4 in Asia [17, 27, 28].
In Latin America, C. parapsilosis blood stream isolates
have rarely been reported to be resistant to fluconazole.
A recent study evaluating a total of 672 episodes of
candidemia in 21 medical centers from 7 countries in
Latin America found that the fluconazole MIC value for
90 % of 178 strains of C parapsilosis was 1.0 mg/mL,
and only 2 strains exhibited susceptibility-dose depend-
ence against this drug [5]. In Brazil, the largest multicen-
ter study ever published on the epidemiology of
candidemia evaluated a total of 712 episodes of candide-
mia and found that all 146 C. parapsilosis strains tested
were susceptible to azoles [7]. Based on those studies we
can state with certainty that the present series of FRCP
candidemia represents the largest experience with this
emergent pathogen in our region.
C. parapsilosis (sensu stricto) has been described as
the most prevalent C. parapsilosis complex species in
both superficial and invasive human infections, and C.
orthopsilosis and C. metapsilosis are responsible for
less than 10 % of the C. parapsilosis group infections
in reported in different series [29–35]. Accordingly,
13 out of 14 of our C. parapsilosis isolates available
Table 1 Epidemiological and clinical characteristics of 40 ICU patients with fungemia caused by fluconazole-resistant C. parapsilosis
(FRCP) and fluconazole-susceptible Candida species (FSC)
FRCP (N = 21) FSCa (N = 19) P value
Age (years) - median (range) 70 (23–91) 76 (35–90) 0.311
Gender female - n (%) 7 (33.3) 8 (42.1) 0.567
Time to candidemia – median/range 22 (0–83) 25 (7–134) 0.185
Apache II score – median/range 14 (3–29) 16 (3–30) 0.138
Death up to 30 days after candidemia (%) 9 (42.9) 9 (47.4) 0.78
Comorbidities - n (%)
Cancer 5 (23.8) 2 (10.5) 0.270
Pulmonary disease 9 (42.9) 11 (57.9) 0.342
Cardiac disease 6 (28.6) 3 (15.8) 0.557
Diabetes mellitusb 11 (52.4) 2 (10.5) 0.013
Renal failure 4 (19.0) 3 (15.8) 1.000
Previous exposure to medical procedures and medicines - n (%)
Short-term catheter 21 (100.0) 17 (89.5) 0.424
Catheter tip positive 4 (19.0) 3 (15.8) 1.000
Previous hemodialysis 3 (14.3) 1 (5.3) 0.673
Prior surgery 12 (61.9) 10 (52.6) 0.775
Mechanical ventilation 15 (71.4) 14 (73.7) 0.873
Parenteral nutrition 7 (33.3) 1 (5.3) 0.059
Previous Hospitalization 4 (19) 8 (42.1) 0.112
Antibiotics 10 (47.6) 8 (42.1) 0.726
Steroids 8 (38.1) 7 (36.8) 0.942
Any antifungal drug 7 (33.3) 3 (15.8) 0.361
Fluconazole 4 (19.0) 3 (15.8) 1.000
aall Candida strains considered susceptible to fluconazole by the Vitek 2 system. bvariable identified as independent factor associated with infection by FRCP
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for molecular identification were identified as C.
parapsilosis (sensu stricto).
It is well established that C. parapsilosis is a com-
mensal of human skin that can be transmitted horizon-
tally via contaminated external sources and hands of
health care workers [36]. We tried to identify risk factors
associated with episodes of candidemia caused by FRCP,
but our findings were limited by the small population
size and casuistic nature of this study as well as the ab-
sence of environmental sampling data and the absence
of a survey of Candida colonization among patients and
health care workers. By multivariate analysis, diabetes
was the only medical condition found to be independ-
ently associated with FRCP. In the present study, central
catheters were not associated with FRCP; furthermore,
they were almost universally present in the patients who
developed candidemia, regardless of whether the causa-
tive Candida strain was susceptibility to fluconazole
(97.5 %, 39 of 40 episodes). However, considering that
most patients with FRCP fungemia were not previously
exposed to fluconazole, we still propose that the present
outbreak was probably a series of catheter-related
fungemias that occurred when a resistant strain of C
parapsilosis was exogenously acquired by the patients
during their hospitalization (15 to 40 days before devel-
oping candidemia) through contact with health care
workers that were putatively colonized by this emergent
pathogen.
The identification of diabetes as a risk factor of infec-
tion by FRCP in our series may be explained by two
aspects: (i) this medical condition may increase the
number of opportunities and the intensity of physical
contact between health care workers and patients to ap-
propriately monitor this metabolic disease both clinically
and through laboratory tests; (ii) diabetic patients are
more prone to colonization by S. aureus and eventually
Candida, facilitating a putative episode of colonization by
a hospital acquired fluconazole-resistant Candida strain.
Conclusion
We were able to report the first outbreak of fluconazole
resistant C parapsilosis strains involving adult ICU pa-
tients without a previous history of long exposition to
triazoles. The clustering of incident cases in the ICU
and molecular typing of strains strongly suggested the
horizontal transmission of FRCP. Despite apparently
uncommon, resistance of C parapsilosis to fluconazole has
been increasingly reported and accurate vigilant monitor-
ing for new nosocomial strains of FRCP is required.
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